IDH2 and central nervous system cancer: IDH-mutant glioblastomas tend to develop from previously diagnosed WHO grade II or III gliomas and appear in patients younger than 50 years of age, while IDH-wild type glioblastomas appear de novo in patients with median age of 60 years (3, 11).